



***Bordetella pertussis* Infection and Vaccination**

Guest Editor:

Dr. Magdalena A. Berkowska

Department of Immunology,
Leiden University Medical Centre
(LUMC), 2333 ZA Leiden, The
Netherlands

Deadline for manuscript
submissions:

25 May 2024

Message from the Guest Editor

Dear Colleagues,

Pertussis or whooping cough is an acute infection of the respiratory tract caused by the bacterium *Bordetella pertussis* (Bp). Despite good vaccination coverage, it remains a disease with one of the highest residual morbidity and mortality, and it is especially dangerous for infants and young children. At present, not only is the number of pertussis cases increasing, but the Bp carriership in the human population also remains high. Several attempts have been made to improve current vaccination strategies, such as optimizing the composition of current acellular vaccines or testing alternative vaccination routes. This Special Issue of *Vaccines* focuses on research that aims to understand immune responses to Bp infection and vaccination, which can shed light on the high pertussis incidence and provide strategies for better pertussis management at the population level. Submissions to this Special Issue can be studies that either evaluate current pertussis vaccines or are aiming to improve them. Research in both human and animal models are welcome.

Dr. Magdalena A. Berkowska
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com